Jacobs Levy Equity Management Inc. Has $1.19 Million Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Jacobs Levy Equity Management Inc. trimmed its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 34.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 314,939 shares of the company's stock after selling 163,501 shares during the quarter. Jacobs Levy Equity Management Inc. owned 0.46% of Amylyx Pharmaceuticals worth $1,190,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its holdings in Amylyx Pharmaceuticals by 144.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 140,559 shares of the company's stock valued at $455,000 after acquiring an additional 83,048 shares during the last quarter. American Century Companies Inc. lifted its holdings in Amylyx Pharmaceuticals by 181.8% in the 4th quarter. American Century Companies Inc. now owns 59,310 shares of the company's stock valued at $224,000 after acquiring an additional 38,261 shares during the last quarter. Dimensional Fund Advisors LP acquired a new stake in Amylyx Pharmaceuticals in the 4th quarter valued at about $205,000. Barclays PLC lifted its holdings in Amylyx Pharmaceuticals by 91.1% in the 3rd quarter. Barclays PLC now owns 84,572 shares of the company's stock valued at $274,000 after acquiring an additional 40,319 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new stake in Amylyx Pharmaceuticals in the 4th quarter valued at about $793,000. 95.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Leerink Partners raised shares of Amylyx Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their price target for the company from $4.00 to $10.00 in a report on Wednesday, May 7th. Mizuho upped their price objective on shares of Amylyx Pharmaceuticals from $7.00 to $8.00 and gave the company an "outperform" rating in a research note on Wednesday, May 14th. HC Wainwright upped their price objective on shares of Amylyx Pharmaceuticals from $12.00 to $16.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Finally, Leerink Partnrs raised shares of Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, May 6th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $9.83.

Amylyx Pharmaceuticals Stock Performance

Shares of NASDAQ AMLX traded down $0.16 during mid-day trading on Thursday, reaching $5.27. The company had a trading volume of 99,213 shares, compared to its average volume of 883,520. The stock has a fifty day moving average of $4.24 and a two-hundred day moving average of $4.21. The company has a market capitalization of $470.04 million, a price-to-earnings ratio of -1.38 and a beta of -0.60. Amylyx Pharmaceuticals, Inc. has a 12-month low of $1.58 and a 12-month high of $7.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.03. Sell-side analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current fiscal year.

Insider Transactions at Amylyx Pharmaceuticals

In other news, CEO Joshua B. Cohen sold 21,490 shares of the stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $3.47, for a total value of $74,570.30. Following the completion of the sale, the chief executive officer now directly owns 3,355,280 shares of the company's stock, valued at $11,642,821.60. This represents a 0.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO James M. Frates sold 10,896 shares of the stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $3.47, for a total transaction of $37,809.12. Following the completion of the sale, the chief financial officer now directly owns 290,988 shares of the company's stock, valued at $1,009,728.36. This trade represents a 3.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 48,980 shares of company stock valued at $168,627 over the last three months. 11.70% of the stock is owned by corporate insiders.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.